Gapping up
In reaction to earnings/guidance:
- MRVL +19%, PDD +15.1%, GPS +11.9%, WDAY +9.4% (also names new CFO), LGF.A +2.8%, BAH +2.4%, ARCE +1.7%, ADSK +1.2%
Other news:
- PDSB +23.5% (announces interim data on PDS0101)
- GNLX +6.5% (announces publication of topline data from Phase 2 VIRO-15 Trial)
- PARA +5.6% (controlling shareholder secures $125 mln investment)
- BOH +4.2% (to move to S&P SmallCap 600 from S&P MidCap 400)
- GERN +3.8% (NDA submission on track for June 2023)
- HCM +3.6% (Takeda Pharma and HUTCHMED receive NDA for Fruquintinib for treatment of previously treated metastatic colorectal cancer granted Priority Review; HCM also Highlights Presentations at the 2023 ASCO Annual Meeting)
- IMAB +3% (announces phase 1b/2 study results of patients with advanced NSCLC)
- SGML +3% (delivers on Zero Tailings strategy receives first payment and obtains premium pricing for sale of green lithium at 9% of LIOH Index)
- GPCR +2% (initiates Phase 2a study of GSBR-1290)
- CGEM +2% (to present first monotherapy clinical data for CLN-619)
- CSTR +2% (completes $10 million common stock repurchase authorization and $20 million new authorization)
- F +1.9% (reaches agreement with TSLA providing Ford EV customers access to Tesla Superchargers)
- TEVA +1.5% (exploring options for bowel inflammation drug including a potential sale according to Bloomberg)
- ZNTL +1.4% (Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting)
- CUE +1.3% (presents data from phase 1 trials of CUE-101)
Analyst comments:
- UWMC +4.1% (upgraded to Buy from Hold at Jefferies)
- GH +3.9% (upgraded to Buy from Neutral at Citigroup)
- NEWR +2.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)